Ryan Holstead to Humans
This is a "connection" page, showing publications Ryan Holstead has written about Humans.
Connection Strength
0.171
-
Holstead RG. Utility of Large Language Models to Produce a Patient-Friendly Summary From Oncology Consultations. JCO Oncol Pract. 2024 Sep; 20(9):1157-1159.
Score: 0.034
-
Holstead RG, Kartolo BA, Hopman WM, Baetz TD. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Res. 2021 06 01; 31(3):258-263.
Score: 0.027
-
Holstead R, Kartolo A, Baetz T. Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. Curr Oncol. 2020 12 02; 28(1):52-59.
Score: 0.026
-
Holstead RG, Robinson AG. Discussing Serious News Remotely: Navigating Difficult Conversations During a Pandemic. JCO Oncol Pract. 2020 07; 16(7):363-368.
Score: 0.025
-
Holstead R, Rasul R, Golden A, Kamdar D, Ghaly M, Teckie S, Frank D, Fantasia J, Seetharamu N. Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas. Future Oncol. 2020 Feb; 16(6):199-207.
Score: 0.025
-
Kartolo A, Holstead RG, Duran I, Robinson AG, Vera-Badillo FE. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. Urology. 2021 11; 157:8-14.
Score: 0.007
-
Kartolo A, Deluce J, Holstead R, Hopman W, Lenehan J, Baetz T. Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. J Immunother. 2021 05 01; 44(4):167-174.
Score: 0.007
-
Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. J Immunother. 2021 01; 44(1):41-48.
Score: 0.007
-
Kartolo A, Holstead R, Hopman W, Baetz T. Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma. Immunotherapy. 2021 02; 13(3):217-225.
Score: 0.007
-
Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Robinson A, Baetz T. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy. Immunotherapy. 2020 08; 12(11):785-798.
Score: 0.006